VIEKIRA XR - (200MG;8.33MG;50MG;33.33MG ; TABLET,EXTENDED RELEASE)

Generic Name	DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR	**Innovator**	Abbvie
Dosage	200MG;8.33MG;50MG;33.33MG ; TABLET,EXTENDED RELEASE	**Branded US Sales**	Less Than $1000 mn
Probable FTF	None	**Known Para IV Filers**	None
Other ANDA developers	None	**Tentative Approvals**	None
Final Approvals	None	**Generic Launches**	None
Indication	VIEKIRA XR includes dasabuvir, a hepatitis C virus non-nucleoside NS5B palm polymerase inhibitor, ombitasvir, a hepatitis C virus NS5A inhibitor, paritaprevir, a hepatitis C virus NS3/4A protease inhibitor, and ritonavir, a CYP3A inhibitor and is indicated for the treatment of adult patients with chronic hepatitis C virus (HCV): • genotype 1b infection without cirrhosis or with compensated cirrhosis • genotype 1a infection without cirrhosis or with compensated cirrhosis for use in combination with ribavirin.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.